The Biotech Voyager

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. The best way to support the show - check out our sponsor! 👇 This episode is brought to you by LabThread. Use the code VOYAGER3 to 3 months FREE (on a 12 month plan) labthread.com

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to 3 months FREE (on a 12 month plan)

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to 3 months FREE (on a 12 month plan)

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to get a special discount at labthread.com

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before they're big news. This broadcast is brought to you by LabThread. Get a 3 month trial at labthread.com using code VOYAGER3

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to get a special discount at labthread.com

Welcome to the Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. This episode is brought to you by LabThread. Use the code VOYAGER3 to get a special discount at labthread.com

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities and emerging technologies. From AI-powered antibody discovery to neutrophil cell therapies, the conversation spans cutting-edge innovation while maintaining critical scientific scrutiny. The episode opens with Big Hat Biosciences' impressive $75 million Series C raise, examining their AI-driven platform for antibody drug conjugate development. The hosts explore how Big Hat's cyclical approach integrates automated wet lab experimentation with AI analysis to iteratively improve therapeutic candidates. The discussion contextualizes AI's role in drug discovery, distinguishing between AI for molecular design versus AI for data analysis and experimental optimization. With backing from major pharmaceutical companies including Amgen, BMS, Eli Lilly, and Merck, and fresh patient dosing in Phase I trials, Big Hat represents a significant validation signal for AI-enabled therapeutic development. The conversation continues with Basecamp Research's massive $140 million Series C, exploring their Eden AI model trained on 9.7 trillion nucleotide tokens from ethically sourced genomic data across 30+ countries. The hosts examine how this comprehensive genetic diversity dataset could enable more effective in vivo CAR-T therapies for solid tumors by identifying candidates with broader patient population applicability. The discussion probes the technical challenges of translating genomic data into functional therapeutics while acknowledging the ambitious nature of in vivo cell therapy approaches. Additional signals include AvenCell's $47 million raise for their universal switchable CAR-T platform, which achieved 71% overall response rates in relapsed/refractory AML using adapter molecules that can target multiple antigens. The hosts examine Scarlet Therapeutics' DARPA-funded program developing smart red blood cells that sense environmental conditions and deliver therapeutics accordingly. Lyft Therapeutics emerges from rebranding with neutrophil cell therapies, though the hosts express significant skepticism about the six to twelve hour lifespan challenge inherent to neutrophil-based therapeutics. AC Immune's active immunotherapy for Parkinson's demonstrates 100% antibody response rates at 100 weeks, prompting debate about terminology distinctions between vaccines and active immunotherapies. The episode features an interview with Ryan from LabThread discussing laboratory software challenges and the future of lab automation, followed by examination of Anthropic's Claude-led discovery of a potential new gene editing mechanism and the A16Z Academy as an alternative to traditional university education for aspiring biotech professionals. Listeners will gain insight into how AI is transforming both therapeutic development and laboratory operations, the critical importance of therapeutic lifespan in cell therapy design, the evolving role of government funding through programs like DARPA and ARPA-H, and why the distinction between prophylactic vaccines and therapeutic active immunotherapies matters for understanding emerging modalities. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #AI #drugdiscovery #CARTtherapy #genetherapy #antibodies #celltherapy #activeimmunotherapy #labautomation

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts navigate an exceptionally busy day in biotech, examining multiple groundbreaking signals across diverse therapeutic modalities. From gene therapies that transform the liver into drug factories to innovative biomaterials that dissolve over time, the conversation spans the cutting edge of biotechnology innovation. The episode opens with an in-depth analysis of ViroNexus, a company developing a revolutionary AAV-based gene therapy for acute lymphoblastic leukemia. Rather than infusing T-cell engagers directly, ViroNexus delivers a transgene that transforms hepatocytes into factories that continuously produce and secrete these therapeutics into the bloodstream. The hosts examine the striking 100% response rate at nine months in three patients, while carefully contextualizing both the promise and significant questions surrounding this biofactory approach. The discussion explores a critical challenge: how do you turn off a therapeutic that's designed to produce drugs for years when targeting healthy B cells could lead to prolonged immunosuppression? The conversation moves through Acro Biosciences' selective RIPK2 inhibitor for ulcerative colitis, examining how targeted inhibition of inflammatory signaling cascades offers straightforward solutions to complex diseases. The hosts then explore Biactica's non-PROTAC oral protein degrader for glioblastoma, highlighting how this orally bioavailable, blood-brain barrier-crossing therapeutic represents a new frontier in targeting previously undruggable proteins through degradation rather than inhibition. Additional signals include Anixa's dual approach combining cancer vaccines with chimeric endocrine receptor therapy for breast cancer, Dualitas' bispecific antibodies that achieve synergistic effects by targeting proximal cell surface proteins, and Dialibrid's innovative silk-polyurethane biomaterial that provides structural support for cell therapies before dissolving over time. The episode concludes with a paper of the day segment examining dual-targeted CAR-T approaches for glioblastoma that simultaneously eliminate both tumor cells and the immunosuppressive myeloid shield. Listeners will gain insight into the promise and challenges of biofactory therapeutics, the expanding toolkit of protein degradation technologies, the importance of controllable expression systems in gene therapy, and why targeting the tumor microenvironment may be as critical as targeting cancer cells themselves. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #genetherapy #proteindegraders #glioblastoma #bispecificantibodies #biomaterials #celltherapy

Welcome to The Biotech Voyager. It's the show that covers what's next in biotech, mapping the early-stage signals before their big news. Hosted by Benjamin McLeod and Jeff Martin, PhD. In this episode, the hosts examine a striking clinical trial result that has generated significant attention in the cell therapy and oncology communities. The discussion centers on a therapeutic approach that has achieved a 100% response rate at nine months in early patient data, a result that stands out dramatically even in a field that has seen remarkable advances in recent years. The conversation explores both the promise and the important caveats surrounding this data. While a 100% response rate represents an extraordinary outcome compared to existing therapies where 70% response rates are considered exceptional, the hosts carefully contextualize this finding within the reality of early clinical development. The result comes from just three patients, making it a preliminary signal rather than definitive proof of efficacy. The discussion examines what constitutes meaningful evidence in early-stage trials and how to interpret small patient cohorts while maintaining appropriate scientific skepticism. The episode delves into the durability aspect of these responses, with patients showing sustained therapeutic benefit out to approximately 260 days following a single infusion. This durability is particularly noteworthy in the context of cell-based therapies, where persistence and long-term function remain critical challenges. The hosts also note the favorable safety profile, with no dose limiting toxicities observed in these initial patients, though questions remain about longer-term follow-up and broader patient populations. Listeners will gain insight into how to evaluate early-stage clinical data in cell therapy, the significance of response rates and durability in assessing therapeutic potential, and why promising preliminary results require careful interpretation before drawing definitive conclusions about clinical impact. New episodes every Tuesday and Thursday at 11:00 AM. #biotech #celltherapy #clinicaltrials #oncology #immunotherapy #durability